Parenteral drug delivery
Promising active pharmaceutical ingredients (API) continue to emerge from drug discovery laboratories.
For all these API – from small molecules to pieces of messenger RNA – the next challenge is delivery. Is it suitable for an oral dosage form? Does it need to be encapsulated in a polymer or lipid? Or does it degrade easily – and therefore require modification prior to parenteral administration?
Evonik has helped drug developers address such questions for several decades, with a wide range of services and solutions for advanced parenteral drug delivery. This includes expert advice and end-to-end assistance, from feasibility studies and process development, to the supply of low volumes of drugs for clinical trials, to high-volume commercial manufacturing. Evonik collaborates with customers to create bioresorbable implants and devices, lipid nanoparticles, polymeric microparticles, in-situ-forming systems, micelles and more. These can be tailored according to indication, route of administration and API properties – mitigating side effects, and ensuring the drug is delivered at efficacious levels for days, weeks or even months.
Evonik’s parenteral drug delivery skills and resources are concentrated at two centers of excellence:
Evonik Birmingham Laboratories in Birmingham (Alabama, USA), focuses on polymer-based microparticles.
Evonik Vancouver Laboratories in Vancouver (British Columbia, Canada), specializes in lipid nanoparticle (LNP) formulations. After the first clinical trial phase, responsibility for these products is transferred from Burnaby to Birmingham.
Evonik Birmingham Laboratories
Evonik acquired SurModics Pharmaceuticals in November 2011. The company was originally established in 2005 as Brookwood Pharmaceuticals, a spin-off of the non-profit Southern Research Institute’s drug development and delivery division. Its extensive experience in polymeric microparticles, combined with state-of-the-art cGMP-certified infrastructure and IP-protected technologies, has strengthened Evonik’s position as a partner to the pharmaceutical and biotech industries.
Evonik Vancouver Laboratories
In 2016, Evonik acquired Transferra Nanosciences, Inc. The enterprise was founded in 1991, and was previously named Northern Lipids, Inc. Today, Evonik Vancouver Laboratories is a contract development and manufacturing organization (CDMO), and offers chemistry, manufacturing and controls services to organizations researching and developing pharmaceuticals. Its unique expertise in lipid-based nanoparticle (LNP) drug delivery systems complements Evonik’s polymer-based parenteral portfolio.